

# 2021 Statement of Financial Position

Phoenix Bioinformatics Corporation  
As of December 31, 2021

Prepared by Connie NG

# 2021 Statement of Financial Position

## Phoenix Bioinformatics Corporation

As of December 31, 2021

Accrual Basis

DEC 31, 2021

### Assets

#### Current Assets

##### Cash and Cash Equivalents

BioCyc Account Citibank	183,672
Incoming Funds Citibank	110,504
Operations Citibank	475,689
Schwab Cash Account	714
Schwab Investment Account	925,286
RepBase Account Citibank	55,533
CIPRES Account Citibank	25,558
MorphoBank Account Citibank	21,755
<b>Total Cash and Cash Equivalents</b>	<b>1,798,711</b>

Accounts Receivable	247,960
---------------------	---------

Prepaid Expenses	6,669
------------------	-------

<b>Total Current Assets</b>	<b>2,053,340</b>
-----------------------------	------------------

#### Fixed Assets

Database and Software	1,709,922
Accum Depr - Database and Software	(1,134,740)
Computer Equipment	31,291
Accum Depr - Computer Equipment	(21,237)
<b>Total Fixed Assets</b>	<b>585,237</b>

<b>Total Assets</b>	<b>2,638,578</b>
---------------------	------------------

### Liabilities and Net Assets

#### Liabilities

##### Current Liabilities

Accounts Payable	23,311
Accrued Expense CalChoice	310
Accrued Leave	109,633
Accrued Earned BioCyc Revenue Payable to SRI	91,420
BioCyc Unearned Revenue	274,118
Due to Employees	(606)
Unearned or Deferred Revenue	931,512
Accrued Earned RepBase Revenue Payable to GIRI	29,959
RepBase Unearned Revenue	127,492
MorphoBank Unearned Revenue	17,772
CIPRES Unearned Revenue	11,042
Accrued Earned CIPRES Revenue	1
Capital One Credit Card	8,784
Bankfeeds - Stripe 2026	400

DEC 31, 2021

Brex Credit Card	23
<b>Total Current Liabilities</b>	<b>1,625,170</b>
<b>Total Liabilities</b>	<b>1,625,170</b>
<b>Net Assets</b>	
<b>Unrestricted</b>	
Undesignated	441,823
Operating Reserve Fund	571,584
<b>Total Unrestricted</b>	<b>1,013,407</b>
<b>Total Net Assets</b>	<b>1,013,407</b>
<b>Total Liabilities and Net Assets</b>	<b>2,638,578</b>

# 2021 Statement of Activities

## Phoenix Bioinformatics Corporation For the year ended December 31, 2021 Accrual Basis

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
<b>Income</b>			
Program Service Fees	59,685	-	59,685
Consulting Services	13,762	-	13,762
Foundation and Trust Grants	25,428	-	25,428
Individ, Business Contributions	78	-	78
BioCyc Subscription Revenue	70,139	-	70,139
<b>Program Subscriptions - TAIR</b>			
Subscription - Country and Consortiums	372,406	-	372,406
Corporate	127,338	-	127,338
Nonprofit and Academic	668,217	-	668,217
Individual and Lab	38,723	-	38,723
<b>Total Program Subscriptions - TAIR</b>	<b>1,206,684</b>	<b>-</b>	<b>1,206,684</b>
Wire Transfer Service Charge	4,080	-	4,080
RepBase Subscription Revenue	24,885	-	24,885
MorphoBank Membership Fee	14,129	-	14,129
CIPRES Subscription Revenue	4,262	-	4,262
<b>Total Income</b>	<b>1,423,130</b>	<b>-</b>	<b>1,423,130</b>
<b>Cost of Goods Sold</b>			
Subaward Expenses	35,487	-	35,487
<b>Total Cost of Goods Sold</b>	<b>35,487</b>	<b>-</b>	<b>35,487</b>
<b>Operating Expenses</b>			
<b>Employee Costs</b>			
Salaries and Wages	1,287,285	-	1,287,285
Vacation Expense	6,361	-	6,361
Payroll Taxes	97,908	-	97,908
Employee Benefits	67,494	-	67,494
401k Plan Contributions	91,316	-	91,316
Recruitment	1,858	-	1,858
Staff Development	42	-	42
Worker's Compensation Insurance	1,029	-	1,029
<b>Total Employee Costs</b>	<b>1,553,293</b>	<b>-</b>	<b>1,553,293</b>
Software Licenses & Services	67,498	-	67,498
<b>Subcontract Services</b>			
Business Consulting Services	15,361	-	15,361
<b>Total Subcontract Services</b>	<b>15,361</b>	<b>-</b>	<b>15,361</b>
<b>Meeting and Travel</b>			
Board-Related Expenses	399	-	399
Conference, Convention, Meeting	5,971	-	5,971

	UNRESTRICTED	TEMPORARILY RESTRICTED	TOTAL
Meals and Entertainment	203	-	203
Travel	940	-	940
<b>Total Meeting and Travel</b>	<b>7,513</b>	<b>-</b>	<b>7,513</b>
Facilities and Equipment	15,257	-	15,257
Professional Fees	14,688	-	14,688
Insurance - Liability, D and O	1,959	-	1,959
Subscriptions and References	245	-	245
Office Supplies	638	-	638
License and Registration Fees	155	-	155
Transaction and Wire Fees	8,428	-	8,428
Audit & Tax Preparation Fees	3,425	-	3,425
WFH Stipends	7,800	-	7,800
<b>Total Operating Expenses</b>	<b>1,696,261</b>	<b>-</b>	<b>1,696,261</b>
<b>Operating Income</b>	<b>(308,618)</b>	<b>-</b>	<b>(308,618)</b>
<b>Other Income / (Expense)</b>			
Depreciation Expense	(148,073)	-	(148,073)
Capitalized PhyloGenes Software Dev.	148,562	-	148,562
Credit Card Rebates	1,300	-	1,300
Interest-Savings, Short-term CD	-	-	-
Interest and Dividends Earned (Investments)	9,018	-	9,018
Unrealized Gain (Loss) on Investments	43,337	-	43,337
<b>Total Other Income / (Expense)</b>	<b>54,144</b>	<b>-</b>	<b>54,144</b>
<b>Increase (Decrease) in Net Assets</b>	<b>(254,475)</b>	<b>-</b>	<b>(254,475)</b>

# Statement of Cash Flows

## Phoenix Bioinformatics Corporation For the year ended December 31, 2021

2021

---

### Cash Flows from Operating Activities

Receipts from customers	(356,773)
Payments to suppliers and employees	(1,326,093)
Cash receipts from other operating activities	9,019
<b>Total Cash Flows from Operating Activities</b>	<b>(1,673,848)</b>

### Cash Flows from Investing Activities

Proceeds from sale of property, plant and equipment	6
Payment for property, plant and equipment	(352,643)
Other cash items from investing activities	(39,235)
<b>Total Cash Flows from Investing Activities</b>	<b>(391,871)</b>

### Cash Flows from Financing Activities

Other cash items from financing activities	2,110,320
<b>Total Cash Flows from Financing Activities</b>	<b>2,110,320</b>

---

<b>Net Cash Flows</b>	<b>44,601</b>
-----------------------	---------------

### Cash Balances

Cash and cash equivalents at beginning of period	828,425
Cash and cash equivalents at end of period	873,025
Net change in cash for period	44,601